Status:
COMPLETED
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-99 years
Brief Summary
The primary objective of this observational study is to document and describe current treatment regimens and disease progression of patients with Multiple Myeloma (MMY). The aim of this registry is to...
Detailed Description
There is a lack of objective data relating to variation in treatment practices and resource utilisation for Multiple Myeloma (MMY) patients between countries. This void continues to hamper attempts to...
Eligibility Criteria
Inclusion
- \- Requires commencement of a new line of treatment for MMY at any stage, regardless of type of therapy selected.
Exclusion
- Patients currently participating in another investigational study or clinical trial.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
2396 Patients enrolled
Trial Details
Trial ID
NCT01241396
Start Date
October 1 2010
End Date
November 1 2014
Last Update
June 20 2016
Active Locations (159)
Enter a location and click search to find clinical trials sorted by distance.
1
Algiers, Algeria
2
Constantine, Algeria
3
Oran, Algeria
4
Sétif, Algeria